Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Acta Diabetologica
Published in: Acta Diabetologica 11/2017

01-11-2017 | Short Communication

Kidney disease measures are associated with the burden of coronary atherosclerosis, independently of diabetes

Authors: Maria Maddalena D’Errico, Antonio Mangiacotti, Daniele Graziano, Valentina Massa, Pamela Piscitelli, Gianluigi Vendemiale, Francesca Viazzi, Roberto Pontremoli, Aldo Russo, Nicola Marchese, Carlo Vigna, Salvatore De Cosmo

Published in: Acta Diabetologica | Issue 11/2017

Login to get access

Excerpt

Several lines of evidence suggest that increased urinary albumin excretion and reduced glomerular filtration rate (GFR) are independently associated with an increased risk of coronary artery disease (CAD) and mortality in general population as well as in patients with diabetes [1]. It has been recently shown that albuminuria correlates with the presence and severity of coronary atherosclerosis [2] and predicts adverse cardiovascular outcome in patients with CAD [3]. …
Literature
1.
De Cosmo S, Lamacchia O, Pacilli A et al (2014) Normoalbuminuric renal impairment and all-cause mortality in type 2 diabetes mellitus. Acta Diabetol 51(4):687–689CrossRefPubMed
2.
Rein P, Vonbank A, Saely CH et al (2011) Relation of albuminuria to angiographically determined coronary arterial narrowing in patients with and without type 2 diabetes mellitus and stable or suspected coronary artery disease. Am J Cardiol 107(8):1144–1148CrossRefPubMed
3.
Kunimura A, Ishii H, Uetani T et al (2016) Prognostic value of albuminuria on cardiovascular outcomes after elective percutaneous coronary intervention. Am J Cardiol 117(5):714–719CrossRefPubMed
4.
Natali A, Boldrini B, Baldi S et al (2014) Impact of mild to moderate reductions of glomerular filtration rate on coronary artery disease severity. Nutr Metab Cardiovasc Dis 24(6):681–688CrossRefPubMed
5.
Hage FG, Venkataraman R, Zoghbi GJ et al (2009) The scope of coronary heart disease in patients with chronic kidney disease. J Am Coll Cardiol 53(23):2129–2140CrossRefPubMed
Metadata
Title
Kidney disease measures are associated with the burden of coronary atherosclerosis, independently of diabetes
Authors
Maria Maddalena D’Errico
Antonio Mangiacotti
Daniele Graziano
Valentina Massa
Pamela Piscitelli
Gianluigi Vendemiale
Francesca Viazzi
Roberto Pontremoli
Aldo Russo
Nicola Marchese
Carlo Vigna
Salvatore De Cosmo
Publication date
01-11-2017
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 11/2017
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-017-1022-x

Other articles of this Issue 11/2017

Acta Diabetologica 11/2017 Go to the issue

Original Article

Enteroviruses in blood of patients with type 1 diabetes detected by integrated cell culture and reverse transcription quantitative real-time PCR

Original Article

Retinal thickness as a marker of disease progression in longitudinal observation of patients with Wolfram syndrome

Case Report

Acute esophageal necrosis (black esophagus): a case report and literature review

Original Article

Joint modeling of longitudinal autoantibody patterns and progression to type 1 diabetes: results from the TEDDY study

Original Article

Clinical characteristics and risk factors for retinal diabetic neurodegeneration in type 2 diabetes

Original Article

Association between lipoprotein(a) level and type 2 diabetes: no evidence for a causal role of lipoprotein(a) and insulin
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits